Difference between revisions of "Team:DLUT China B"

(添加项目描述内容)
(初次布局。)
Line 1: Line 1:
−
{{DLUT_China_B}}
+
<!DOCTYPE html>
−
<html>
+
<html lang="en">
 +
<head>
 +
    <meta charset="UTF-8">
 +
    <title>2018 iGEM_DLUT_B</title>
 +
    <link rel="stylesheet" href="https://2018.igem.org/wiki/index.php?title=Template:DLUT_China_B/css/style.css&action=raw&ctype=text/css">
 +
    <link rel="stylesheet" href="https://2018.igem.org/wiki/index.php?title=Template:DLUT_China_B/css/nav.css&action=raw&ctype=text/css">
 +
    <link rel="stylesheet" href="https://2018.igem.org/wiki/index.php?title=Template:DLUT_China_B/css/bubbles.css&action=raw&ctype=text/css">
 +
    <link rel="stylesheet" href="https://2018.igem.org/wiki/index.php?title=Template:DLUT_China_B/css/slideshow.css&action=raw&ctype=text/css">
  
 +
    <script src="https://2018.igem.org/wiki/index.php?title=Template:DLUT_China_B/js/slideshow.js&action=raw&ctype=javascript"></script>
 +
    <script src="https://2018.igem.org/wiki/index.php?title=Template:DLUT_China_B/js/bubbles.js&action=raw&ctype=javascript"></script>
 +
    <script src="https://2018.igem.org/wiki/index.php?title=Template:DLUT_China_B/js/typed.js&action=raw&ctype=javascript"></script>
 +
</head>
 +
<body>
 +
<div id="dlutb">
 +
    <div id="header">
 +
        <div id="nav">
 +
            <ul class="menu">
 +
                <li>
 +
                    <a href="#">Professional Services</a>
 +
                    <ul class="subMenu">
 +
                        <li>
 +
                            <a href="#">Professional Services</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Partners</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Training</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Technical Support</a>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
                <li>
 +
                    <a href="#">Products</a>
 +
                    <ul class="subMenu">
 +
                        <li>
 +
                            <a href="#">Embedded Devices</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Reference software stack & SDK</a>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
                <li>
 +
                    <a href="#">Solutions</a>
 +
                    <ul class="subMenu">
 +
                        <li>
 +
                            <a href="#">Automotive</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Automation</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Medical</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Libraries, Tools & IDE</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">UI design technologies</a>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
                <li>
 +
                    <a href="#">Professional Services</a>
 +
                    <ul class="subMenu">
 +
                        <li>
 +
                            <a href="#">Professional Services</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Partners</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Training</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Technical Support</a>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
                <li>
 +
                    <a href="#">Products</a>
 +
                    <ul class="subMenu">
 +
                        <li>
 +
                            <a href="#">Embedded Devices</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Reference software stack & SDK</a>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
                <li>
 +
                    <a href="#">Solutions</a>
 +
                    <ul class="subMenu">
 +
                        <li>
 +
                            <a href="#">Automotive</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Automation</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Medical</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Libraries, Tools & IDE</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">UI design technologies</a>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
                <li>
 +
                    <a href="#">Professional Services</a>
 +
                    <ul class="subMenu">
 +
                        <li>
 +
                            <a href="#">Professional Services</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Partners</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Training</a>
 +
                        </li>
 +
                        <li>
 +
                            <a href="#">Technical Support</a>
 +
                        </li>
 +
                    </ul>
 +
                </li>
 +
            </ul>
 +
        </div>
 +
        <br>
 +
        <div class="title" id="teamName">DLUT China B</div>
 +
        <div id="typed">
 +
            <span id="slogan"></span>
 +
        </div>
  
 +
        <script>
 +
            let options = {
 +
                strings: ["We can put our slogan here", "Or other things to be said"],
 +
                typeSpeed: 100,
 +
                loop: true,
 +
                startDelay: 100,
 +
                backSpeed: 50
 +
            };
 +
            let typed = new Typed("#slogan", options);
 +
        </script>
 +
        <br>
 +
        <a class="btn" id="start">Get Started</a>
 +
        <script>
 +
            $('#start').click(function () {
 +
                $('html,body').animate({scrollTop: $('#meetUs').offset().top-60}, 500);
 +
            });
 +
        </script>
 +
    </div>
  
 +
    <div>
 +
        <h2 class="title" id="meetUs">We are concerned about the world's largest potential group of chronic kidney disease</h2>
 +
        <div class="mainText">
 +
            <p>According to statistics of the World Health Organization, about 1.2 million people died of kidney disease in
 +
                2015
 +
                worldwide, which is 32% higher than that in 2005. Among them, diabetes and hypertensive patients are the
 +
                largest
 +
                potential victims of chronic kidney disease. Of the new ESRD patients in the United States in the past 10
 +
                years, 58%
 +
                are from diabetes and hypertension patients. If we do not intervene in patients with early-stage
 +
                hypertension or
 +
                diabetes, it will cause a dramatic deterioration of renal function with a mortality rate up to 90%. However,
 +
                if the
 +
                patient's kidney status can be monitored at any time, with early detection and timely medical treatment, up
 +
                to 70%
 +
                of the disease may be reversed. Therefore, it is of great social significance to monitor the renal status of
 +
                patients with early-stage hypertension and diabetes.</p>
 +
            <p>At this stage, the excretion rate of urinary microalbumin (mALB) is mainly used to diagnose diabetic
 +
                nephropathy and
 +
                hypertensive nephropathy. Although the detection method is relatively perfect, it has the following
 +
                disadvantages:</p>
 +
            <ol>
 +
                <li>The accuracy and specificity of mALB in diagnosing DN are not high, and urinary tract infection and
 +
                    other
 +
                    factors can increase the excretion rate of urinary albumin, resulting in high misdiagnosis and missed
 +
                    diagnosis.
 +
                </li>
 +
                <li>When the mALB is abnormal, DN has progressed to Phase III. It is not sufficient to use this indicator to
 +
                    monitor
 +
                    the occurrence and development of DN.
 +
                </li>
 +
                <li>Renal impairment in hypertension occurs first in the renal tubules, and then in the glomerulus. Urine
 +
                    microalbumin mainly reflects glomerular filtration impairment and is not sensitive to renal tubular
 +
                    injury.
 +
                </li>
 +
            </ol>
 +
        </div>
 +
    </div>
  
−
<div class="column" >
+
    <div id="fixed1"></div>
−
<h1> Welcome to wiki page for 2018 DLUT China B </h1>
+
−
<p>This page is under construction at the moment.</p>
+
  
−
<img src="https://static.igem.org/mediawiki/2018/2/29/T--DLUT_China_B--logo.png" height="335">
+
    <div>
−
<p>This is the wiki page of 2018 DLUT China B.</p>
+
        <h2 class="title">We use β<sub>2</sub>M for high sensitivity monitoring of the kidneys</h2>
−
<!--<img src="http://placehold.it/1080x320/c4baba/e4dede">-->
+
        <div class="mainText">
−
</div>
+
            <p>In order to solve the problems in the above detection methods, we conducted a multi-study investigation to
 +
                find a new
 +
                type of indicator β<sub>2</sub>M which has higher sensitivity to early kidney damage. β<sub>2</sub>M is a
 +
                small
 +
                molecule globulin produced by lymphocytes, platelets, and polymorphonuclear leukocytes. It can be freely
 +
                filtered
 +
                from the glomerulus and is absorbed by the proximal tubular in 99.9% . Under normal condition, the excretion
 +
                of
 +
                β<sub>2</sub>M in urine(U-β<sub>2</sub>M) is very small which is no more than 0.25mg/L. U-β<sub>2</sub>M
 +
                excretion
 +
                is increased in early urine of diabetic patients with stage I hypertension and diabetes. With the deepening
 +
                of the
 +
                renal damage, β<sub>2</sub>M accumulates in patients and continue increase. Therefore, the detection of
 +
                U-β<sub>2</sub>M in patients with a risk of kidney disease, such as diabetes and hypertension, can achieve
 +
                real-time
 +
                monitoring of the condition of the kidneys, as well as the discovery of early nephropathy to prevent
 +
                irreversible
 +
                damage to the kidneys.</p>
 +
        </div>
 +
    </div>
  
−
<div class="column full_size">
+
    <div id="fixed2"></div>
−
<h3>Description</h3>
+
−
<br>
+
−
<h4>We are concerned about the world's largest potential group of chronic kidney disease.</h4>
+
−
<p>According to statistics of the World Health Organization, about 1.2 million people died of kidney disease in 2015 worldwide, which is 32% higher than that in 2005. Among them, diabetes and hypertensive patients are the largest potential victims of chronic kidney disease. Of the new ESRD patients in the United States in the past 10 years, 58% are from diabetes and hypertension patients. If we do not intervene in patients with early-stage hypertension or diabetes, it will cause a dramatic deterioration of renal function with a mortality rate up to 90%. However, if the patient's kidney status can be monitored at any time, with early detection and timely medical treatment, up to 70% of the disease may be reversed. Therefore, it is of great social significance to monitor the renal status of patients with early-stage hypertension and diabetes.</p>
+
−
<p>At this stage, the excretion rate of urinary microalbumin (mALB) is mainly used to diagnose diabetic nephropathy and hypertensive nephropathy. Although the detection method is relatively perfect, it has the following disadvantages:</p>
+
−
<ol>
+
−
    <li>The accuracy and specificity of mALB in diagnosing DN are not high, and urinary tract infection and other factors can increase the excretion rate of urinary albumin, resulting in high misdiagnosis and missed diagnosis.</li>
+
−
    <li>When the mALB is abnormal, DN has progressed to Phase III. It is not sufficient to use this indicator to monitor the occurrence and development of DN.</li>
+
−
    <li>Renal impairment in hypertension occurs first in the renal tubules, and then in the glomerulus. Urine microalbumin mainly reflects glomerular filtration impairment and is not sensitive to renal tubular injury.</li>
+
−
</ol>
+
−
<br>
+
−
<h4>We use β<sub>2</sub>M for high sensitivity monitoring of the kidneys.</h4>
+
−
<p>In order to solve the problems in the above detection methods, we conducted a multi-study investigation to find a new type of indicator β<sub>2</sub>M which has higher sensitivity to early kidney damage. β<sub>2</sub>M is a small molecule globulin produced by lymphocytes, platelets, and polymorphonuclear leukocytes. It can be freely filtered from the glomerulus and is absorbed by the proximal tubular in 99.9% . Under normal condition, the excretion of β<sub>2</sub>M in urine(U-β<sub>2</sub>M) is very small which is no more than 0.25mg/L. U-β<sub>2</sub>M excretion is increased in early urine of diabetic patients with stage I hypertension and diabetes. With the deepening of the renal damage, β<sub>2</sub>M accumulates in patients and continue increase. Therefore, the detection of U-β<sub>2</sub>M in patients with a risk of kidney disease, such as diabetes and hypertension, can achieve real-time monitoring of the condition of the kidneys, as well as the discovery of early nephropathy to prevent irreversible damage to the kidneys.</p>
+
−
<br>
+
−
<h4>What kind of a work we want to complete?</h4>
+
−
<p>Patients with diabetes for about 5 years or those with Hypertension for 5 to 10 years are at high risk of chronic kidney disease and are at risk of renal impairment at any time. Since diabetics and hypertensives are usually treated at home in early stages , routine blood and urine tests are rarely performed and the U-β<sub>2</sub>M indicator is unknown. This has led many patients to miss the opportunity for early intervention and control. Our work enables these patients to easily monitor their own renal function status at home through the U-β<sub>2</sub>M test. In addition, we can use mobile devices to conduct a brief analysis of the patient's renal function and give medical advice.</p>
+
−
<br>
+
−
<h4>For U-β<sub>2</sub>M we developed a suitable detection method</h4>
+
−
<p>In this project, we combined strongly specific nanobodies with high-sensitivity liquid crystal detection to develop a visual detection method, thereby enabling accurate quantification or semiquantification of microgram-levelU- β<sub>2</sub>M. Firstly, we use nanobody to specifically bind to β<sub>2</sub>M. Compared with conventional antibodies, nanobody is a smaller molecular,less susceptible to denaturation, but still has intact antigen binding properties. In addition, nanobodies can be expressed by <i>E. coli</i> , which make the cost of production is greatly reduced. What's more, we use the birefringence of liquid crystal molecules. The liquid crystal application that we are familiar with is liquid crystal display, but this is to change the arrangement of the liquid crystal molecules through the electric current, thus show different light signals. Here, we modify the liquid crystal cell substrate with antibodies. After combining antigens, the micro-environment of the liquid crystal cell platform changes, resulting in a significant difference in color or brightness , the visualization of detection is achieved. </p>
+
−
<p>This project will propose a low-cost, portable and visible method for monitoring early renal injury and provide medical advice for patients with hypertension and diabetes.
+
−
</p>
+
−
</div>
+
  
−
<!--
+
    <div>
−
<div class="column full_size" >
+
        <h2 class="title">What kind of a work we want to complete?</h2>
 +
        <div class="mainText">
 +
            <p>Patients with diabetes for about 5 years or those with Hypertension for 5 to 10 years are at high risk of
 +
                chronic
 +
                kidney disease and are at risk of renal impairment at any time. Since diabetics and hypertensives are
 +
                usually
 +
                treated at home in early stages , routine blood and urine tests are rarely performed and the U-β<sub>2</sub>M
 +
                indicator is unknown. This has led many patients to miss the opportunity for early intervention and control.
 +
                Our
 +
                work enables these patients to easily monitor their own renal function status at home through the
 +
                U-β<sub>2</sub>M
 +
                test. In addition, we can use mobile devices to conduct a brief analysis of the patient's renal function and
 +
                give
 +
                medical advice.</p>
 +
        </div>
 +
    </div>
  
−
<h3>Before you start</h3>
+
    <div id="fixed3"></div>
−
<p> Please read the following pages:</p>
+
−
<ul>
+
−
<li>  <a href="https://2018.igem.org/Competition">Competition Hub</a> </li>
+
−
<li> <a href="https://2018.igem.org/Competition/Deliverables/Wiki">Wiki Requirements page</a></li>
+
−
<li> <a href="https://2018.igem.org/Resources/Template_Documentation">Template documentation</a></li>
+
−
</ul>
+
−
</div>
+
  
 +
    <div>
 +
        <h2 class="title">For U-β<sub>2</sub>M we developed a suitable detection method</h2>
 +
        <div class="mainText">
 +
            <p>In this project, we combined strongly specific nanobodies with high-sensitivity liquid crystal detection to
 +
                develop a
 +
                visual detection method, thereby enabling accurate quantification or semiquantification of microgram-levelU-
 +
                β<sub>2</sub>M. Firstly, we use nanobody to specifically bind to β<sub>2</sub>M. Compared with conventional
 +
                antibodies, nanobody is a smaller molecular,less susceptible to denaturation, but still has intact antigen
 +
                binding
 +
                properties. In addition, nanobodies can be expressed by <i>E. coli</i> , which make the cost of production
 +
                is
 +
                greatly reduced. What's more, we use the birefringence of liquid crystal molecules. The liquid crystal
 +
                application
 +
                that we are familiar with is liquid crystal display, but this is to change the arrangement of the liquid
 +
                crystal
 +
                molecules through the electric current, thus show different light signals. Here, we modify the liquid
 +
                crystal cell
 +
                substrate with antibodies. After combining antigens, the micro-environment of the liquid crystal cell
 +
                platform
 +
                changes, resulting in a significant difference in color or brightness , the visualization of detection is
 +
                achieved.
 +
            </p>
 +
            <p>This project will propose a low-cost, portable and visible method for monitoring early renal injury and
 +
                provide
 +
                medical advice for patients with hypertension and diabetes.
 +
            </p>
 +
        </div>
 +
    </div>
  
−
<div class="clear extra_space"></div>
+
    <div id="footer">
−
<div class="line_divider"></div>
+
        <div id="address">
−
<div class="clear extra_space"></div>
+
            <h3>Address</h3>
−
 
+
            <p>No.2 Linggong Road, Ganjingzi District, Dalian City, Liaoning Province, P.R.C., 116024</p>
−
 
+
        </div>
−
 
+
    </div>
−
<div class="column full_size" >
+
−
<h3> Styling your wiki </h3>
+
−
<p>You may style this page as you like or you can simply leave the style as it is. You can easily keep the styling and edit the content of these default wiki pages with your project information and completely fulfill the requirement to document your project.</p>
+
−
<p>While you may not win Best Wiki with this styling, your team is still eligible for all other awards. This default wiki meets the requirements, it improves navigability and ease of use for visitors, and you should not feel it is necessary to style beyond what has been provided.</p>  
+
  
 +
    <div id="back" class="btn"></div>
 +
    <script>
 +
        $('#back').click(function () {
 +
            $('html').animate( {scrollTop: 0}, 500);
 +
        });
 +
        document.onscroll=function () {
 +
            if($('html').scrollTop()>600)
 +
                document.getElementById("back").style.display="block";
 +
            else
 +
                document.getElementById("back").style.display="none";
 +
        };
 +
    </script>
 
</div>
 
</div>
−
 
+
</body>
−
 
+
−
 
+
−
 
+
−
<div class="clear extra_space"></div>
+
−
 
+
−
 
+
−
 
+
−
<div class="column third_size" >
+
−
 
+
−
<h3> Uploading pictures and files </h3>
+
−
<p> You must upload any pictures and files to the iGEM 2018 server. Remember to keep all your pictures and files within your team's namespace or at least include your team's name in the file name. </p>
+
−
 
+
−
 
+
−
<p>When you upload, set the "Destination Filename" to <b> T--YourOfficialTeamName--NameOfFile.jpg</b>. (If you don't do this, someone else might upload a different file with the same "Destination Filename", and your file would be erased!)</p>
+
−
 
+
−
<div class="button_link">
+
−
<a href="https://2018.igem.org/Special:Upload">
+
−
UPLOAD FILES
+
−
</a>
+
−
</div>
+
−
 
+
−
</div>
+
−
 
+
−
<div class="column third_size" >
+
−
<h3> Wiki template information </h3>
+
−
<p>We have created these wiki template pages to help you get started and to help you think about how your team will be evaluated. You can find a list of all the pages tied to awards here at the <a href="https://2018.igem.org/Judging/Pages_for_Awards">Pages for awards</a> link. You must edit these pages to be evaluated for medals and awards, but ultimately the design, layout, style and all other elements of your team wiki is up to you!</p>
+
−
 
+
−
</div>
+
−
 
+
−
 
+
−
 
+
−
<div class="column third_size" >
+
−
<div class="highlight decoration_B_full">
+
−
<h3> Editing your wiki </h3>
+
−
<p>On this page you can document your project, introduce your team members, document your progress and share your iGEM experience with the rest of the world! </p>
+
−
<p>Use WikiTools - Edit in the black menu bar to edit this page</p>
+
−
 
+
−
<div class="button_link">
+
−
<a href="https://2018.igem.org/wiki/index.php?title=Team:DLUT_China_B&action=edit">
+
−
EDIT PAGE
+
−
</a>
+
−
</div>
+
−
 
+
−
 
+
−
</div>
+
−
</div>
+
−
 
+
−
 
+
−
 
+
−
 
+
−
 
+
−
<div class="clear extra_space"></div>
+
−
<div class="line_divider"></div>
+
−
<div class="clear extra_space"></div>
+
−
 
+
−
 
+
−
 
+
−
<div class="column two_thirds_size" >
+
−
<h3>Tips</h3>
+
−
<p>This wiki will be your team’s first interaction with the rest of the world, so here are a few tips to help you get started: </p>
+
−
<ul>
+
−
<li>State your accomplishments! Tell people what you have achieved from the start. </li>
+
−
<li>Be clear about what you are doing and how you plan to do this.</li>
+
−
<li>You have a global audience! Consider the different backgrounds that your users come from.</li>
+
−
<li>Make sure information is easy to find; nothing should be more than 3 clicks away.  </li>
+
−
<li>Avoid using very small fonts and low contrast colors; information should be easy to read.  </li>
+
−
<li>Start documenting your project as early as possible; don’t leave anything to the last minute before the Wiki Freeze. For a complete list of deadlines visit the <a href="https://2018.igem.org/Calendar">iGEM 2018 calendar</a> </li>
+
−
<li>Have lots of fun! </li>
+
−
</ul>
+
−
</div>
+
−
 
+
−
 
+
−
<div class="column third_size">
+
−
<div class="highlight decoration_A_full">
+
−
<h3>Inspiration</h3>
+
−
<p> You can also view other team wikis for inspiration! Here are some examples:</p>
+
−
<ul>
+
−
<li> <a href="https://2014.igem.org/Team:SDU-Denmark/"> 2014 SDU Denmark </a> </li>
+
−
<li> <a href="https://2014.igem.org/Team:Aalto-Helsinki">2014 Aalto-Helsinki</a> </li>
+
−
<li> <a href="https://2014.igem.org/Team:LMU-Munich">2014 LMU-Munich</a> </li>
+
−
<li> <a href="https://2014.igem.org/Team:Michigan"> 2014 Michigan</a></li>
+
−
<li> <a href="https://2014.igem.org/Team:ITESM-Guadalajara">2014 ITESM-Guadalajara </a></li>
+
−
<li> <a href="https://2014.igem.org/Team:SCU-China"> 2014 SCU-China </a></li>
+
−
</ul>
+
−
</div>
+
−
</div>
+
−
-->
+
−
 
+
−
 
+
−
 
+
 
</html>
 
</html>

Revision as of 06:39, 7 September 2018

<!DOCTYPE html> 2018 iGEM_DLUT_B

We are concerned about the world's largest potential group of chronic kidney disease

According to statistics of the World Health Organization, about 1.2 million people died of kidney disease in 2015 worldwide, which is 32% higher than that in 2005. Among them, diabetes and hypertensive patients are the largest potential victims of chronic kidney disease. Of the new ESRD patients in the United States in the past 10 years, 58% are from diabetes and hypertension patients. If we do not intervene in patients with early-stage hypertension or diabetes, it will cause a dramatic deterioration of renal function with a mortality rate up to 90%. However, if the patient's kidney status can be monitored at any time, with early detection and timely medical treatment, up to 70% of the disease may be reversed. Therefore, it is of great social significance to monitor the renal status of patients with early-stage hypertension and diabetes.

At this stage, the excretion rate of urinary microalbumin (mALB) is mainly used to diagnose diabetic nephropathy and hypertensive nephropathy. Although the detection method is relatively perfect, it has the following disadvantages:

  1. The accuracy and specificity of mALB in diagnosing DN are not high, and urinary tract infection and other factors can increase the excretion rate of urinary albumin, resulting in high misdiagnosis and missed diagnosis.
  2. When the mALB is abnormal, DN has progressed to Phase III. It is not sufficient to use this indicator to monitor the occurrence and development of DN.
  3. Renal impairment in hypertension occurs first in the renal tubules, and then in the glomerulus. Urine microalbumin mainly reflects glomerular filtration impairment and is not sensitive to renal tubular injury.

We use β2M for high sensitivity monitoring of the kidneys

In order to solve the problems in the above detection methods, we conducted a multi-study investigation to find a new type of indicator β2M which has higher sensitivity to early kidney damage. β2M is a small molecule globulin produced by lymphocytes, platelets, and polymorphonuclear leukocytes. It can be freely filtered from the glomerulus and is absorbed by the proximal tubular in 99.9% . Under normal condition, the excretion of β2M in urine(U-β2M) is very small which is no more than 0.25mg/L. U-β2M excretion is increased in early urine of diabetic patients with stage I hypertension and diabetes. With the deepening of the renal damage, β2M accumulates in patients and continue increase. Therefore, the detection of U-β2M in patients with a risk of kidney disease, such as diabetes and hypertension, can achieve real-time monitoring of the condition of the kidneys, as well as the discovery of early nephropathy to prevent irreversible damage to the kidneys.

What kind of a work we want to complete?

Patients with diabetes for about 5 years or those with Hypertension for 5 to 10 years are at high risk of chronic kidney disease and are at risk of renal impairment at any time. Since diabetics and hypertensives are usually treated at home in early stages , routine blood and urine tests are rarely performed and the U-β2M indicator is unknown. This has led many patients to miss the opportunity for early intervention and control. Our work enables these patients to easily monitor their own renal function status at home through the U-β2M test. In addition, we can use mobile devices to conduct a brief analysis of the patient's renal function and give medical advice.

For U-β2M we developed a suitable detection method

In this project, we combined strongly specific nanobodies with high-sensitivity liquid crystal detection to develop a visual detection method, thereby enabling accurate quantification or semiquantification of microgram-levelU- β2M. Firstly, we use nanobody to specifically bind to β2M. Compared with conventional antibodies, nanobody is a smaller molecular,less susceptible to denaturation, but still has intact antigen binding properties. In addition, nanobodies can be expressed by E. coli , which make the cost of production is greatly reduced. What's more, we use the birefringence of liquid crystal molecules. The liquid crystal application that we are familiar with is liquid crystal display, but this is to change the arrangement of the liquid crystal molecules through the electric current, thus show different light signals. Here, we modify the liquid crystal cell substrate with antibodies. After combining antigens, the micro-environment of the liquid crystal cell platform changes, resulting in a significant difference in color or brightness , the visualization of detection is achieved.

This project will propose a low-cost, portable and visible method for monitoring early renal injury and provide medical advice for patients with hypertension and diabetes.